Perspective Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $280.8M
- Price
- $2.46
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.24%
- Volume
- 1.3M
About
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Quick stats
Shares outstanding114.2M
Computed float95.1M
Float / shares83.3%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000728387
AI Summary
AI-generated1/33
minorneutralclinical trial
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
Perspective Therapeutics announced that cohort-level safety and efficacy data for its lead alpha-particle therapy [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors were accepted for an oral presentation at the NANETS 2026 symposium on November 5.
The data cover Cohorts 1-3 of the ongoing NCT05636618 dose-escalation/expansion study; interim results through an April 17, 2026 cutoff were previously shown at ASCO 2026.
This is a conference-scheduling announcement rather than new clinical data; the incremental read comes when the updated cohort results are actually presented.